Abstract
Background
N-Acetylcysteine (NAC) is reported to have potential for preventing of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography. However, the effectiveness of NAC in preventing CIN in patients undergoing contrast-enhanced computed tomography (CT) is still controversial. We conducted a meta-analysis of relevant randomized controlled trials (RCTs) to further examine this issue.
Methods
RCTs were identified by computerized searching in PubMed, EMBASE, SCOPUS, and Cochrane databases. Two reviewers independently assessed the methodological quality of each study. A meta-analysis was performed to evaluate the effectiveness of NAC in preventing CIN in patients undergoing CT. The primary outcome was the incidence of contrast-induced nephropathy, and the requirement for dialysis. The secondary outcome was the change of serum creatinine.
Results
Six randomized controlled trials were identified with a total of 496 patients meeting the criteria for this study. Prophylactic administration of NAC in patients with serum creatinine above 1.2 mg/dL undergoing contrast-enhanced CT, along with hydration, reduced the risk of CIN (relative risk 0.20; 95 % confidence interval: 0.07–0.57). Requirement for dialysis was not significantly different between the NAC group and the control group.
Conclusions
This review provides evidence of the efficacy of NAC in preventing the incidence of CIN and recommends that NAC be more widely used in high-risk patients undergoing contrast-enhanced CT. On the basis of the evidence reviewed, further research involving large RCTs may be warranted.
Similar content being viewed by others
References
Parfrey PS, Griffiths SM, Barrett BJ et al (1989) Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320:143–149
Weisbord SD, Mor MK, Resnick AL et al (2008) Prevention, incidence, and outcomes of contrast-induced acute kidney injury. Arch Intern Med 168:1325–1332
Mitchell AM, Jones AE, Tumlin JA, Kline JA (2010) Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol 5:4–9
Thomsen HS, Morcos SK (2006) Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines. Eur Radiol 16:1835–1840
Sandstede JJ, Roth A, Machann W, Kaupert C, Hahn D (2007) Evaluation of the nephrotoxicity of iodixanol in patients with predisposing factors to contrast medium induced nephropathy referred for contrast enhanced computed tomography. Eur J Radiol 63:120–123
Huber W, Eckel F, Hennig M et al (2006) Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 239:793–804
Baliga R, Ueda N, Walker PD, Shah SV (1997) Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 29:465–477
Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC (2008) Meta-analysis:effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148:284–294
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Burns KE, Priestap F, Martin C (2010) N-acetylcysteine in critically ill patients undergoing contrast-enhanced computed tomography: a randomized trial. Clin Nephrol 74:323–326
Poletti PA, Saudan P, Platon A et al (2007) I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 189:687–692
Sar F, Saler T, Ecebay A, Saglam ZA, Ozturk S, Kazancioglu R (2010) The efficacy of n-acetylcysteine in preventing contrast-induced nephropathy in type 2 diabetic patients without nephropathy. J Nephrol 23:478–482
Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180–184
Hsu TF, Huang MK, Yu SH et al (2012) N-acetylcysteine for the prevention of contrast-induced nephropathy in the emergency department. Intern Med 51:2709–2714
Kitzler TM, Jaberi A, Sendlhofer G et al (2012) Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial. Wien Klin Wochenschr 124:312–319
Perkins BA, Nelson RG, Ostrander BE et al (2005) Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 16:1404–1412
Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G (2009) High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 122(874):e9–e15
Mueller C, Buerkle G, Buettner HJ et al (2002) Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162:329–336
Thiele H, Hildebrand L, Schirdewahn C et al (2010) Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) trial. J Am Coll Cardiol 55:2201–2209
Brown JR, Block CA, Malenka DJ, O’Connor GT, Schoolwerth AC, Thompson CA (2009) Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv 2:1116–1124
Herts BR, Schneider E, Poggio ED, Obuchowski NA, Baker ME (2008) Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels. Radiology 248:106–113
Rehman T, Fought J, Solomon R (2008) N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol 3:1610–1614
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Appendix: Search methods for identification of studies
Appendix: Search methods for identification of studies
Relevant trials will be obtained from the following sources without language restriction:-
-
For the MEDLINE and EMBASE search, we used the following combination of keywords:
[Renal failure or kidney failure to include all subheadings] and [contrast media or iopamidol or iodine or ioxaglic acid or iodine compounds or iohexol or urography or tomography or X ray computed] and [clinical trial or randomized controlled trial] and [N-Acetylcysteine or acetylcysteine].
-
For the PubMed, Cochrane Library Database, and Scopus searches, we used the search words:
Acetylcysteine, radio induced or contrast induced, renal insufficiency or renal failure or kidney injury or nephropathy, randomized controlled trial, and computed tomography.
Rights and permissions
About this article
Cite this article
Wu, MY., Hsiang, HF., Wong, CS. et al. The effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials. Int Urol Nephrol 45, 1309–1318 (2013). https://doi.org/10.1007/s11255-012-0363-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-012-0363-1